A journey through the lectin pathway of complement—MBL and beyond

Immunological Reviews

Volumn 274, Issue 1, 2016, Pages 74-97

  Garred, Peter ^a   Genster, Ninette ^a   Pilely, Katrine ^a   Bayarri Olmos, Rafael ^a   Rosbjerg, Anne ^a   Ma, Ying Jie ^a   Skjoedt, Mikkel Ole ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

collectins; ficolins; lectin pathway of complement; mannose binding lectin; MASPs

Indexed keywords

ALPHA 2 MACROGLOBULIN; ANTITHROMBIN III; BRADYKININ; C REACTIVE PROTEIN; COLLECTIN; COMPLEMENT; COMPLEMENT COMPONENT C1R; COMPLEMENT COMPONENT C1S; COMPLEMENT COMPONENT C1S INHIBITOR; FIBRINOGEN; FICOLIN; FICOLIN 1; FICOLIN 2; FICOLIN 3; KALLIKREIN; KALLIKREIN INHIBITOR; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE 1; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE 2; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE 3; MANNOSE BINDING LECTIN; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PATTERN RECOGNITION RECEPTOR; PENTRAXIN; PROPERDIN; PROTHROMBIN; SERUM AMYLOID P; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN; UNCLASSIFIED DRUG; LECTIN;

ALLELE; ALTERNATIVE RNA SPLICING; BLOOD CLOTTING; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT LECTIN PATHWAY; COMPLEMENT SYSTEM; CRYSTAL STRUCTURE; DNA POLYMORPHISM; EMBRYO DEVELOPMENT; ENDOTHELIUM CELL; ENZYME ACTIVATION; FIBRINOLYSIS; FRAMESHIFT MUTATION; GENETIC ASSOCIATION; GENETIC VARIATION; HOMEOSTASIS; HOST RESISTANCE; HUMAN; KALLIKREIN KININ SYSTEM; MEDIATOR RELEASE; MOLECULAR RECOGNITION; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; THROMBOCYTE ACTIVATION; TISSUE DISTRIBUTION; ANIMAL; HOST PATHOGEN INTERACTION; INNATE IMMUNITY; METABOLISM;

ANIMALS; BLOOD COAGULATION; COLLECTINS; COMPLEMENT PATHWAY, MANNOSE-BINDING LECTIN; HOMEOSTASIS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; LECTINS; MANNOSE-BINDING LECTIN; MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASES; PLATELET ACTIVATION;

EID: 84992451610     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12468     Document Type: Review

References (205)

1. Dommett RM, Klein N, Turner MW. Mannose-binding lectin in innate immunity: past, present and future. Tissue Antigens. 2006;68:193–209.
2. Ohtani K, Suzuki Y, Wakamiya N. Biological functions of the novel collectins CL-L1, CL-K1, and CL-P1. J Biomed Biotechnol. 2012;2012:493945.
3. Endo Y, Matsushita M, Fujita T. The role of ficolins in the lectin pathway of innate immunity. Int J Biochem Cell Biol. 2011;43:705–712.
4. Yongqing T, Drentin N, Duncan RC, Wijeyewickrema LC, Pike RN. Mannose-binding lectin serine proteases and associated proteins of the lectin pathway of complement: two genes, five proteins and many functions? Biochim Biophys Acta. 2012;1824:253–262.
5. Ma YJ, Hein E, Munthe-Fog L, et al. Soluble collectin-12 (CL-12) is a pattern recognition molecule initiating complement activation via the alternative pathway. J Immunol. 2015;195:3365–3373.
6. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11:785–797.
7. Axelgaard E, Jensen L, Dyrlund TF, et al. Investigations on collectin liver 1. J Biol Chem. 2013;288:23407–23420.
8. Ma YJ, Skjoedt M-O, Garred P. Collectin-11/MASP complex formation triggers activation of the lectin complement pathway–the fifth lectin pathway initiation complex. J Innate Immun. 2013;5:242–250.
9. Matsushita M, Endo Y, Fujita T. Cutting Edge: complement-activating complex of ficolin and mannose-binding lectin-associated serine protease. J Immunol. 2000;164:2281–2284.
10. Matsushita M, Kuraya M, Hamasaki N, Tsujimura M, Shiraki H, Fujita T. Activation of the lectin complement pathway by H-ficolin (Hakata antigen). J Immunol. 2002;168:3502–3506.
11. Liu Y, Endo Y, Iwaki D, et al. Human M-ficolin is a secretory protein that activates the lectin complement pathway. J Immunol. 2005;175:3150–3156.
12. Avirutnan P, Hauhart RE, Marovich MA, Garred P, Atkinson JP, Diamond MS. Complement-mediated neutralization of dengue virus requires mannose-binding lectin. MBio. 2011;2:e00276–11.
13. Oroszlán G, Kortvely E, Szakács D, et al. MASP-1 and MASP-2 do not activate pro-factor D in resting human blood, whereas MASP-3 is a potential activator: kinetic analysis involving specific MASP-1 and MASP-2 inhibitors. J Immunol. 2016;196:857–865.
14. Zhang J, Yang L, Ang Z, et al. Secreted M-ficolin anchors onto monocyte transmembrane G protein-coupled receptor 43 and cross talks with plasma C-reactive protein to mediate immune signaling and regulate host defense. J Immunol. 2010;185:6899–6910.
15. Ma YJ, Doni A, Hummelshøj T, et al. Synergy between ficolin-2 and pentraxin 3 boosts innate immune recognition and complement deposition. J Biol Chem. 2009;284:28263–28275.
16. Ng PML, Le Saux A, Lee CM, et al. C-reactive protein collaborates with plasma lectins to boost immune response against bacteria. EMBO J. 2007;26:3431–3440.
17. Daigo K, Yamaguchi N, Kawamura T, et al. The proteomic profile of circulating pentraxin 3 (PTX3) complex in sepsis demonstrates the interaction with azurocidin 1 and other components of neutrophil extracellular traps. Mol Cell Proteomics. 2012;11(M111):015073.
18. Garlanda C, Hirsch E, Bozza S, et al. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature. 2002;420:182–186.
19. Tanio M, Wakamatsu K, Kohno T. Binding site of C-reactive protein on M-ficolin. Mol Immunol. 2009;47:215–221.
20. Ma YJ, Doni A, Romani L, et al. Ficolin-1-PTX3 complex formation promotes clearance of altered self-cells and modulates IL-8 production. J Immunol. 2013;191:1324–1333.
21. Ma YJ, Doni A, Skjoedt M-O, et al. Heterocomplexes of mannose-binding lectin and the pentraxins PTX3 or serum amyloid P component trigger cross-activation of the complement system. J Biol Chem. 2011;286:3405–3417.
22. Roy N, Ohtani K, Matsuda Y, et al. Collectin CL-P1 utilizes C-reactive protein for complement activation. Biochim Biophys Acta. 2016;1860:1118–1128.
23. Doni A, Garlanda C, Bottazzi B, Meri S, Garred P, Mantovani A. Interactions of the humoral pattern recognition molecule PTX3 with the complement system. Immunobiology. 2012;217:1122–1128.
24. Burnet FM, McCrea JF. Inhibitory and activating action of normal ferret sera against an influenza virus strain. Aust J Exp Biol Med Sci. 1946;24:277–282.
25. Kawasaki T, Etoh R, Yamashina I. Isolation and characterization of a mannan-binding protein from rabbit liver. Biochem Biophys Res Commun. 1978;81:1018–1024.
26. Super M, Thiel S, Lu J, Levinsky RJ, Turner MW. Association of low levels of mannan-binding protein with a common defect of opsonisation. Lancet (London, England). 1989;2:1236–1239.
27. Sumiya M, Super M, Tabona P, et al. Molecular basis of opsonic defect in immunodeficient children. Lancet (London, England). 1991;337:1569–1570.
28. Sastry K, Herman GA, Day L, et al. The human mannose-binding protein gene. Exon structure reveals its evolutionary relationship to a human pulmonary surfactant gene and localization to chromosome 10. J Exp Med. 1989;170:1175–1189.
29. Guo N, Mogues T, Weremowicz S, Morton CC, Sastry KN. The human ortholog of rhesus mannose-binding protein-A gene is an expressed pseudogene that localizes to chromosome 10. Mamm Genome. 1998;9:246–249.
30. Seyfarth J, Garred P, Madsen HO. The “involution” of mannose-binding lectin. Hum Mol Genet. 2005;14:2859–2869.
31. Taylor ME, Brickell PM, Craig RK, Summerfield JA. Structure and evolutionary origin of the gene encoding a human serum mannose-binding protein. Biochem J. 1989;262:763–771.
32. Palaniyar N, Nadesalingam J, Clark H, Shih MJ, Dodds AW, Reid KBM. Nucleic acid is a novel ligand for innate, immune pattern recognition collectins surfactant proteins A and D and mannose-binding lectin. J Biol Chem. 2004;279:32728–32736.
33. Garred P, Thiel S, Madsen HO, Ryder LP, Jensenius JC, Svejgaard A. Gene frequency and partial protein characterization of an allelic variant of mannan binding protein associated with low serum concentrations. Clin Exp Immunol. 1992;90:517–521.
34. Naito H, Ikeda A, Hasegawa K, et al. Characterization of human serum mannan-binding protein promoter. J Biochem. 1999;126:1004–1012.
35. Larsen F, Madsen HO, Sim RB, Koch C, Garred P. Disease-associated mutations in human mannose-binding lectin compromise oligomerization and activity of the final protein. J Biol Chem. 2004;279:21302–21311.
36. Teillet F, Dublet B, Andrieu J-P, Gaboriaud C, Arlaud GJ, Thielens NM. The two major oligomeric forms of human mannan-binding lectin: chemical characterization, carbohydrate-binding properties, and interaction with MBL-associated serine proteases. J Immunol. 2005;174:2870–2877.
37. Garred P, Larsen F, Madsen H, Koch C. Mannose-binding lectin deficiency–revisited. Mol Immunol. 2003;40:73–84.
38. Mogues T, Ota T, Tauber AI, Sastry KN. Characterization of two mannose-binding protein cDNAs from rhesus monkey (Macaca mulatta): structure and evolutionary implications. Glycobiology. 1996;6:543–550.
39. Garred P, Madsen HO, Kurtzhals JA, et al. Diallelic polymorphism may explain variations of the blood concentration of mannan-binding protein in Eskimos, but not in black Africans. Eur J Immunogenet. 1992;19:403–412.
40. Lipscombe RJ, Sumiya M, Hill AV, et al. High frequencies in African and non-African populations of independent mutations in the mannose binding protein gene. Hum Mol Genet. 1992;1:709–715.
41. Madsen HO, Garred P, Kurtzhals JA, et al. A new frequent allele is the missing link in the structural polymorphism of the human mannan-binding protein. Immunogenetics. 1994;40:37–44.
42. Madsen HO, Garred P, Thiel S, et al. Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol. 1995;155:3013–3020.
43. Madsen HO, Satz ML, Hogh B, Svejgaard A, Garred P. Different molecular events result in low protein levels of mannan-binding lectin in populations from southeast Africa and South America. J Immunol. 1998;161:3169–3175.
44. Garred P, Larsen F, Seyfarth J, Fujita R, Madsen HO. Mannose-binding lectin and its genetic variants. Genes Immun. 2006;7:85–94.
45. Verga Falzacappa MV, Segat L, Puppini B, Amoroso A, Crovella S. Evolution of the mannose-binding lectin gene in primates. Genes Immun. 2004;5:653–661.
46. Terai I, Kobayashi K, Matsushita M, Miyakawa H, Mafune N, Kikuta H. Relationship between gene polymorphisms of mannose-binding lectin (MBL) and two molecular forms of MBL. Eur J Immunol. 2003;33:2755–2763.
47. Roos A, Garred P, Wildenberg ME, et al. Antibody-mediated activation of the classical pathway of complement may compensate for mannose-binding lectin deficiency. Eur J Immunol. 2004;34:2589–2598.
48. Lee S-G, Yum J-S, Moon HM, et al. Analysis of mannose-binding lectin 2 (MBL2) genotype and the serum protein levels in the Korean population. Mol Immunol. 2005;42:969–977.
49. Dean MM, Heatley S, Minchinton RM. Heteroligomeric forms of codon 54 mannose binding lectin (MBL) in circulation demonstrate reduced in vitro function. Mol Immunol. 2006;43:950–961.
50. Garred P, Harboe M, Oettinger T, Koch C, Svejgaard A. Dual role of mannan-binding protein in infections: another case of heterosis? Eur J Immunogenet. 1994;21:125–131.
51. Sandoval JR, Madsen HO, De Stefano G, et al. Extreme high prevalence of a defective mannose-binding lectin (MBL2) genotype in native South American West Andean populations. PLoS ONE. 2014;9:e108943.
52. Verdu P, Barreiro LB, Patin E, et al. Evolutionary insights into the high worldwide prevalence of MBL2 deficiency alleles. Hum Mol Genet. 2006;15:2650–2658.
53. Andersen P, Permin H, Andersen V, et al. Deficiency of somatic hypermutation of the antibody light chain is associated with increased frequency of severe respiratory tract infection in common variable immunodeficiency. Blood. 2005;105:511–517.
54. Fevang B, Mollnes TE, Holm AM, et al. Common variable immunodeficiency and the complement system; low mannose-binding lectin levels are associated with bronchiectasis. Clin Exp Immunol. 2005;142:576–584.
55. Garred P, Pressler T, Madsen HO, et al. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest. 1999;104:431–437.
56. Dorfman R, Sandford A, Taylor C, et al. Complex two-gene modulation of lung disease severity in children with cystic fibrosis. J Clin Invest. 2008;118:1040–1049.
57. Chalmers JD, Fleming GB, Hill AT, Kilpatrick DC. Impact of mannose-binding lectin insufficiency on the course of cystic fibrosis: a review and meta-analysis. Glycobiology. 2011;21:271–282.
58. Bay JT, Sørensen SS, Hansen JM, Madsen HO, Garred P. Low mannose-binding lectin serum levels are associated with reduced kidney graft survival. Kidney Int. 2013;83:264–271.
59. Golshayan D, Wójtowicz A, Bibert S, et al. Polymorphisms in the lectin pathway of complement activation influence the incidence of acute rejection and graft outcome after kidney transplantation. Kidney Int. 2016;89:927–938.
60. Ohtani K, Suzuki Y, Eda S, et al. Molecular cloning of a novel human collectin from liver (CL-L1). J Biol Chem. 1999;274:13681–13689.
61. Keshi H, Sakamoto T, Kawai T, et al. Identification and characterization of a novel human collectin CL-K1. Microbiol Immunol. 2006;50:1001–1013.
62. Selman L, Hansen S. Structure and function of collectin liver 1 (CL-L1) and collectin 11 (CL-11, CL-K1). Immunobiology. 2012;217:851–863.
63. Kawai T, Suzuki Y, Eda S, et al. Molecular cloning of mouse collectin liver 1. Biosci Biotechnol Biochem. 2002;66:2134–2145.
64. Henriksen ML, Brandt J, Andrieu J-P, et al. Heteromeric complexes of native collectin kidney 1 and collectin liver 1 are found in the circulation with MASPs and activate the complement system. J Immunol. 2013;191:6117–6127.
65. Bayarri-Olmos R, Hansen S, Henriksen ML, et al. Genetic variation of COLEC10 and COLEC11 and association with serum levels of collectin liver 1 (CL-L1) and collectin kidney 1 (CL-K1). PLoS ONE. 2015;10:e0114883.
66. Troldborg A, Thiel S, Jensen L, et al. Collectin liver 1 and collectin kidney 1 and other complement-associated pattern recognition molecules in systemic lupus erythematosus. Clin Exp Immunol. 2015;182:132–138.
67. Hansen S, Selman L, Palaniyar N, et al. Collectin 11 (CL-11, CL-K1) is a MASP-1/3-associated plasma collectin with microbial-binding activity. J Immunol. 2010;185:6096–6104.
68. Selman L, Henriksen ML, Brandt J, et al. An enzyme-linked immunosorbent assay (ELISA) for quantification of human collectin 11 (CL-11, CL-K1). J Immunol Methods. 2012;375:182–188.
69. Yoshizaki T, Ohtani K, Motomura W, et al. Comparison of human blood concentrations of collectin kidney 1 and mannan-binding lectin. J Biochem. 2012;151:57–64.
70. Takahashi K, Ohtani K, Larvie M, et al. Elevated plasma CL-K1 level is associated with a risk of developing disseminated intravascular coagulation (DIC). J Thromb Thrombolysis. 2014;38:331–338.
71. Antony JS, Ojurongbe O, Kremsner PG, Velavan TP. Lectin complement protein Collectin 11 (CL-K1) and susceptibility to urinary schistosomiasis. PLoS Negl Trop Dis. 2015;9:e0003647.
72. Rooryck C, Diaz-Font A, Osborn DPS, et al. Mutations in lectin complement pathway genes COLEC11 and MASP1 cause 3MC syndrome. Nat Genet. 2011;43:197–203.
73. Venkatraman Girija U, Furze CM, Gingras AR, et al. Molecular basis of sugar recognition by collectin-K1 and the effects of mutations associated with 3MC syndrome. BMC Biol. 2015;13:27.
74. Drickamer K. Engineering galactose-binding activity into a C-type mannose-binding protein. Nature. 1992;360:183–186.
75. Henriksen ML, Brandt J, Iyer SSC, Thielens NM, Hansen S. Characterization of the interaction between collectin 11 (CL-11, CL-K1) and nucleic acids. Mol Immunol. 2013;56:757–767.
76. Teillet F, Lacroix M, Thiel S, et al. Identification of the site of human mannan-binding lectin involved in the interaction with its partner serine proteases: the essential role of Lys55. J Immunol. 2007;178:5710–5716.
77. Girija UV, Dodds AW, Roscher S, Reid KBM, Wallis R. Localization and characterization of the mannose-binding lectin (MBL)-associated-serine protease-2 binding site in rat ficolin-A: equivalent binding sites within the collagenous domains of MBLs and ficolins. J Immunol. 2007;179:455–462.
78. Laursen TL, Sandahl TD, Støy S, et al. Circulating mannan-binding lectin, M-, L-, H-ficolin and collectin-liver-1 levels in patients with acute liver failure. Liver Int. 2015;35:756–763.
79. Ingels C, Vanhorebeek I, Derese I, et al. The pattern recognition molecule collectin-L1 in critically ill children. Pediatr Res. 2016;80:237–43.
80. Troegeler A, Lugo-Villarino G, Hansen S, et al. Collectin CL-LK is a novel soluble pattern recognition receptor for Mycobacterium tuberculosis. PLoS ONE. 2015;10:e0132692.
81. Farrar CA, Tran D, Li K, et al. Collectin-11 detects stress-induced L-fucose pattern to trigger renal epithelial injury. J Clin Invest. 2016;126:1911–1925.
82. Nakamura K, Funakoshi H, Miyamoto K, Tokunaga F, Nakamura T. Molecular cloning and functional characterization of a human scavenger receptor with C-type lectin (SRCL), a novel member of a scavenger receptor family. Biochem Biophys Res Commun. 2001;280:1028–1035.
83. Ohtani K, Suzuki Y, Eda S, et al. The membrane-type collectin CL-P1 is a scavenger receptor on vascular endothelial cells. J Biol Chem. 2001;276:44222–44228.
84. Nakamura K, Funakoshi H, Tokunaga F, Nakamura T. Molecular cloning of a mouse scavenger receptor with C-type lectin (SRCL)(1), a novel member of the scavenger receptor family. Biochim Biophys Acta. 2001;1522:53–58.
85. Coombs PJ, Graham SA, Drickamer K, Taylor ME. Selective binding of the scavenger receptor C-type lectin to Lewisx trisaccharide and related glycan ligands. J Biol Chem. 2005;280:22993–22999.
86. Mori K, Ohtani K, Jang S, et al. Scavenger receptor CL-P1 mainly utilizes a collagen-like domain to uptake microbes and modified LDL. Biochim Biophys Acta. 2014;1840:3345–3356.
87. Jang S, Ohtani K, Fukuoh A, et al. Scavenger receptor CL-P1 mediates endocytosis by associating with AP-2μ2. Biochim Biophys Acta. 2014;1840:3226–3237.
88. Selman L, Skjodt K, Nielsen O, Floridon C, Holmskov U, Hansen S. Expression and tissue localization of collectin placenta 1 (CL-P1, SRCL) in human tissues. Mol Immunol. 2008;45:3278–3288.
89. Jang S, Ohtani K, Fukuoh A, et al. Scavenger receptor collectin placenta 1 (CL-P1) predominantly mediates zymosan phagocytosis by human vascular endothelial cells. J Biol Chem. 2009;284:3956–3965.
90. Nakamura K, Ohya W, Funakoshi H, et al. Possible role of scavenger receptor SRCL in the clearance of amyloid-beta in Alzheimer’s disease. J Neurosci Res. 2006;84:874–890.
91. Yoshida T, Tsuruta Y, Iwasaki M, Yamane S, Ochi T, Suzuki R. SRCL/CL-P1 recognizes GalNAc and a carcinoma-associated antigen, Tn antigen. J Biochem. 2003;133:271–277.
92. Graham SA, Antonopoulos A, Hitchen PG, et al. Identification of neutrophil granule glycoproteins as Lewis(x)-containing ligands cleared by the scavenger receptor C-type lectin. J Biol Chem. 2011;286:24336–24349.
93. Shepherd VL, Hoidal JR. Clearance of neutrophil-derived myeloperoxidase by the macrophage mannose receptor. Am J Respir Cell Mol Biol. 1990;2:335–340.
94. Ichijo H, Rönnstrand L, Miyagawa K, Ohashi H, Heldin CH, Miyazono K. Purification of transforming growth factor-beta 1 binding proteins from porcine uterus membranes. J Biol Chem. 1991;266:22459–22464.
95. Ichijo H, Hellman U, Wernstedt C, et al. Molecular cloning and characterization of ficolin, a multimeric protein with fibrinogen- and collagen-like domains. J Biol Chem. 1993;268:14505–14513.
96. Matsushita M, Endo Y, Taira S, et al. A novel human serum lectin with collagen- and fibrinogen-like domains that functions as an opsonin. J Biol Chem. 1996;271:2448–2454.
97. Sugimoto R, Yae Y, Akaiwa M, et al. Cloning and characterization of the Hakata antigen, a member of the ficolin/opsonin p35 lectin family. J Biol Chem. 1998;273:20721–20727.
98. Yae Y, Inaba S, Sato H, Okochi K, Tokunaga F, Iwanaga S. Isolation and characterization of a thermolabile beta-2 macroglycoprotein (‘thermolabile substance’ or “Hakata antigen”) detected by precipitating (auto) antibody in sera of patients with systemic lupus erythematosus. Biochim Biophys Acta. 1991;1078:369–376.
99. Endo Y, Sato Y, Matsushita M, Fujita T. Cloning and characterization of the human lectin P35 gene and its related gene. Genomics. 1996;36:515–521.
100. Lu J, Tay PN, Kon OL, Reid KB. Human ficolin: cDNA cloning, demonstration of peripheral blood leucocytes as the major site of synthesis and assignment of the gene to chromosome 9. Biochem J. 1996;313(Pt 2):473–478.
101. Matsushita M, Endo Y, Hamasaki N, Fujita T. Activation of the lectin complement pathway by ficolins. Int Immunopharmacol. 2001;1:359–363.
102. Endo Y, Liu Y, Kanno K, Takahashi M, Matsushita M, Fujita T. Identification of the mouse H-ficolin gene as a pseudogene and orthology between mouse ficolins A/B and human L-/M-ficolins. Genomics. 2004;84:737–744.
103. Ohashi T, Erickson HP. The disulfide bonding pattern in ficolin multimers. J Biol Chem. 2004;279:6534–6539.
104. Hummelshoj T, Fog LM, Madsen HO, Sim RB, Garred P. Comparative study of the human ficolins reveals unique features of Ficolin-3 (Hakata antigen). Mol Immunol. 2008;45:1623–1632.
105. Hummelshoj T, Thielens NM, Madsen HO, Arlaud GJ, Sim RB, Garred P. Molecular organization of human Ficolin-2. Mol Immunol. 2007;44:401–411.
106. Ohashi T, Erickson HP. Oligomeric structure and tissue distribution of ficolins from mouse, pig and human. Arch Biochem Biophys. 1998;360:223–232.
107. Garred P, Honoré C, Ma YJ, et al. The genetics of ficolins. J Innate Immun. 2010;2:3–16.
108. Fujimori Y, Harumiya S, Fukumoto Y, et al. Molecular cloning and characterization of mouse ficolin-A. Biochem Biophys Res Commun. 1998;244:796–800.
109. Honoré C, Rørvig S, Munthe-Fog L, et al. The innate pattern recognition molecule Ficolin-1 is secreted by monocytes/macrophages and is circulating in human plasma. Mol Immunol. 2008;45:2782–2789.
110. Rørvig S, Honore C, Larsson L-I, et al. Ficolin-1 is present in a highly mobilizable subset of human neutrophil granules and associates with the cell surface after stimulation with fMLP. J Leukoc Biol. 2009;86:1439–1449.
111. Honoré C, Rørvig S, Hummelshøj T, Skjoedt M-O, Borregaard N, Garred P. Tethering of Ficolin-1 to cell surfaces through recognition of sialic acid by the fibrinogen-like domain. J Leukoc Biol. 2010;88:145–158.
112. Munthe-Fog L, Hummelshoj T, Honoré C, et al. Variation in FCN1 affects biosynthesis of ficolin-1 and is associated with outcome of systemic inflammation. Genes Immun. 2012;13:515–522.
113. Munthe-Fog L, Hummelshøj T, Hansen BE, et al. The impact of FCN2 polymorphisms and haplotypes on the Ficolin-2 serum levels. Scand J Immunol. 2007;65:383–392.
114. Munthe-Fog L, Hummelshøj T, Ma YJ, et al. Characterization of a polymorphism in the coding sequence of FCN3 resulting in a Ficolin-3 (Hakata antigen) deficiency state. Mol Immunol. 2008;45:2660–2666.
115. Gout E, Garlatti V, Smith DF, et al. Carbohydrate recognition properties of human ficolins: glycan array screening reveals the sialic acid binding specificity of M-ficolin. J Biol Chem. 2010;285:6612–6622.
116. Kjaer TR, Hansen AG, Sørensen UBS, et al. M-ficolin binds selectively to the capsular polysaccharides of Streptococcus pneumoniae serotypes 19B and 19C and of a Streptococcus mitis strain. Infect Immun. 2013;81:452–459.
117. Favier A-L, Gout E, Reynard O, et al. Enhancement of Ebola virus infection via ficolin-1 interaction with the mucin domain of GP glycoprotein. J Virol. 2016;90:5256–5269.
118. Le Y, Lee SH, Kon OL, Lu J. Human L-ficolin: plasma levels, sugar specificity, and assignment of its lectin activity to the fibrinogen-like (FBG) domain. FEBS Lett. 1998;425:367–370.
119. Lynch NJ, Roscher S, Hartung T, et al. L-ficolin specifically binds to lipoteichoic acid, a cell wall constituent of Gram-positive bacteria, and activates the lectin pathway of complement. J Immunol. 2004;172:1198–1202.
120. Ma YG, Cho MY, Zhao M, et al. Human mannose-binding lectin and L-ficolin function as specific pattern recognition proteins in the lectin activation pathway of complement. J Biol Chem. 2004;279:25307–25312.
121. Krarup A, Sørensen UBS, Matsushita M, Jensenius JC, Thiel S. Effect of capsulation of opportunistic pathogenic bacteria on binding of the pattern recognition molecules mannan-binding lectin, L-ficolin, and H-ficolin. Infect Immun. 2005;73:1052–1060.
122. Luo F, Sun X, Wang Y, et al. Ficolin-2 defends against virulent Mycobacteria tuberculosis infection in vivo, and its insufficiency is associated with infection in humans. PLoS ONE. 2013;8:e73859.
123. Pan Q, Chen H, Wang F, et al. L-ficolin binds to the glycoproteins hemagglutinin and neuraminidase and inhibits influenza A virus infection both in vitro and in vivo. J Innate Immun. 2012;4:312–324.
124. Cestari Idos S, Krarup A, Sim RB, Inal JM, Ramirez MI. Role of early lectin pathway activation in the complement-mediated killing of Trypanosoma cruzi. Mol Immunol. 2009;47:426–437.
125. Garlatti V, Belloy N, Martin L, et al. Structural insights into the innate immune recognition specificities of L- and H-ficolins. EMBO J. 2007;26:623–633.
126. Tanio M, Kondo S, Sugio S, Kohno T. Trivalent recognition unit of innate immunity system: crystal structure of trimeric human M-ficolin fibrinogen-like domain. J Biol Chem. 2007;282:3889–3895.
127. Verma A, White M, Vathipadiekal V, et al. Human H-ficolin inhibits replication of seasonal and pandemic influenza A viruses. J Immunol. 2012;189:2478–2487.
128. Brinkmann CR, Jensen L, Dagnæs-Hansen F, et al. Mitochondria and the lectin pathway of complement. J Biol Chem. 2013;288:8016–8027.
129. Jensen ML, Honoré C, Hummelshøj T, Hansen BE, Madsen HO, Garred P. Ficolin-2 recognizes DNA and participates in the clearance of dying host cells. Mol Immunol. 2007;44:856–865.
130. Honoré C, Hummelshoj T, Hansen BE, Madsen HO, Eggleton P, Garred P. The innate immune component ficolin 3 (Hakata antigen) mediates the clearance of late apoptotic cells. Arthritis Rheum. 2007;56:1598–1607.
131. Endo Y, Matsushita M, Fujita T. New insights into the role of ficolins in the lectin pathway of innate immunity. Int Rev Cell Mol Biol. 2015;316:49–110.
132. Hummelshøj T, Munthe-Fog L, Madsen HO, Garred P. Functional SNPs in the human ficolin (FCN) genes reveal distinct geographical patterns. Mol Immunol. 2008;45:2508–2520.
133. Boldt ABW, Sanchez MIN, Stahlke ERS, et al. Susceptibility to leprosy is associated with M-ficolin polymorphisms. J Clin Immunol. 2013;33:210–219.
134. Vander Cruyssen B, Nuytinck L, Boullart L, et al. Polymorphisms in the ficolin 1 gene (FCN1) are associated with susceptibility to the development of rheumatoid arthritis. Rheumatology (Oxford). 2007;46:1792–1795.
135. Haerynck F, Van Steen K, Cattaert T, et al. Polymorphisms in the lectin pathway genes as a possible cause of early chronic Pseudomonas aeruginosa colonization in cystic fibrosis patients. Hum Immunol. 2012;73:1175–1183.
136. Hummelshoj T, Munthe-Fog L, Madsen HO, Fujita T, Matsushita M, Garred P. Polymorphisms in the FCN2 gene determine serum variation and function of Ficolin-2. Hum Mol Genet. 2005;14:1651–1658.
137. Luz PR, Boldt ABW, Grisbach C, Kun JFJ, Velavan TP, Messias-Reason IJT. Association of L-ficolin levels and FCN2 genotypes with chronic Chagas disease. PLoS ONE. 2013;8:e60237.
138. Zhang D-F, Huang X-Q, Wang D, Li Y-Y, Yao Y-G. Genetic variants of complement genes ficolin-2, mannose-binding lectin and complement factor H are associated with leprosy in Han Chinese from Southwest China. Hum Genet. 2013;132:629–640.
139. Eikmans M, de Canck I, van der Pol P, et al. The functional polymorphism Ala258Ser in the innate receptor gene ficolin-2 in the donor predicts improved renal transplant outcome. Transplantation. 2012;94:478–485.
140. Michalski M, Świerzko AS, Pągowska-Klimek I, et al. Primary Ficolin-3 deficiency–is it associated with increased susceptibility to infections? Immunobiology. 2015;220:711–713.
141. Munthe-Fog L, Hummelshøj T, Honoré C, Madsen HO, Permin H, Garred P. Immunodeficiency associated with FCN3 mutation and ficolin-3 deficiency. N Engl J Med. 2009;360:2637–2644.
142. Endo Y, Takahashi M, Iwaki D, et al. Mice deficient in ficolin, a lectin complement pathway recognition molecule, are susceptible to Streptococcus pneumoniae infection. J Immunol. 2012;189:5860–5866.
143. Marchalonis JJ, Schluter SF. Immunoproteins in evolution. Dev Comp Immunol. 1989;13:285–301.
144. Lu J, Marjon KD, Mold C, Du Clos TW, Sun PD. Pentraxins and Fc receptors. Immunol Rev. 2012;250:230–238.
145. Deban L, Jaillon S, Garlanda C, Bottazzi B, Mantovani A. Pentraxins in innate immunity: lessons from PTX3. Cell Tissue Res. 2011;343:237–249.
146. van Asbeck EC, Hoepelman AIM, Scharringa J, Herpers BL, Verhoef J. Mannose binding lectin plays a crucial role in innate immunity against yeast by enhanced complement activation and enhanced uptake of polymorphonuclear cells. BMC Microbiol. 2008;8:229.
147. Kemper C, Atkinson JP, Hourcade DE. Properdin: emerging roles of a pattern-recognition molecule. Annu Rev Immunol. 2010;28:131–155.
148. Matsushita M, Fujita T. Activation of the classical complement pathway by mannose-binding protein in association with a novel C1s-like serine protease. J Exp Med. 1992;176:1497–1502.
149. Thiel S, Vorup-Jensen T, Stover CM, et al. A second serine protease associated with mannan-binding lectin that activates complement. Nature. 1997;386:506–510.
150. Terai I, Kobayashi K, Matsushita M, Fujita T. Human serum mannose-binding lectin (MBL)-associated serine protease-1 (MASP-1): determination of levels in body fluids and identification of two forms in serum. Clin Exp Immunol. 1997;110:317–323.
151. Takahashi M, Endo Y, Fujita T, Matsushita M. A truncated form of mannose-binding lectin-associated serine protease (MASP)-2 expressed by alternative polyadenylation is a component of the lectin complement pathway. Int Immunol. 1999;11:859–863.
152. Dahl MR, Thiel S, Matsushita M, et al. MASP-3 and its association with distinct complexes of the mannan-binding lectin complement activation pathway. Immunity. 2001;15:127–135.
153. Degn SE, Hansen AG, Steffensen R, Jacobsen C, Jensenius JC, Thiel S. MAp44, a human protein associated with pattern recognition molecules of the complement system and regulating the lectin pathway of complement activation. J Immunol. 2009;183:7371–7378.
154. Skjoedt M-O, Hummelshoj T, Palarasah Y, et al. A novel mannose-binding lectin/ficolin-associated protein is highly expressed in heart and skeletal muscle tissues and inhibits complement activation. J Biol Chem. 2010;285:8234–8243.
155. Harmat V, Gál P, Kardos J, et al. The structure of MBL-associated serine protease-2 reveals that identical substrate specificities of C1s and MASP-2 are realized through different sets of enzyme-substrate interactions. J Mol Biol. 2004;342:1533–1546.
156. Teillet F, Gaboriaud C, Lacroix M, Martin L, Arlaud GJ, Thielens NM. Crystal structure of the CUB1-EGF-CUB2 domain of human MASP-1/3 and identification of its interaction sites with mannan-binding lectin and ficolins. J Biol Chem. 2008;283:25715–25724.
157. Dobó J, Harmat V, Beinrohr L, Sebestyén E, Závodszky P, Gál P. MASP-1, a promiscuous complement protease: structure of its catalytic region reveals the basis of its broad specificity. J Immunol. 2009;183:1207–1214.
158. Yongqing T, Wilmann PG, Reeve SB, et al. The x-ray crystal structure of mannose-binding lectin-associated serine proteinase-3 reveals the structural basis for enzyme inactivity associated with the Carnevale, Mingarelli, Malpuech, and Michels (3MC) syndrome. J Biol Chem. 2013;288:22399–22407.
159. Gregory LA, Thielens NM, Matsushita M, et al. The X-ray structure of human mannan-binding lectin-associated protein 19 (MAp19) and its interaction site with mannan-binding lectin and L-ficolin. J Biol Chem. 2004;279:29391–29397.
160. Skjoedt M-O, Roversi P, Hummelshøj T, et al. Crystal structure and functional characterization of the complement regulator mannose-binding lectin (MBL)/ficolin-associated protein-1 (MAP-1). J Biol Chem. 2012;287:32913–32921.
161. Degn SE, Jensen L, Olszowski T, Jensenius JC, Thiel S. Co-complexes of MASP-1 and MASP-2 associated with the soluble pattern-recognition molecules drive lectin pathway activation in a manner inhibitable by MAp44. J Immunol. 2013;191:1334–1345.
162. Rosbjerg A, Munthe-Fog L, Garred P, Skjoedt M-O. Heterocomplex formation between MBL/ficolin/CL-11-associated serine protease-1 and -3 and MBL/ficolin/CL-11-associated protein-1. J Immunol. 2014;192:4352–4360.
163. Paréj K, Hermann A, Donáth N, Závodszky P, Gál P, Dobó J. Dissociation and re-association studies on the interaction domains of mannan-binding lectin (MBL)-associated serine proteases, MASP-1 and MASP-2, provide evidence for heterodimer formation. Mol Immunol. 2014;59:1–9.
164. Degn SE, Thiel S, Nielsen O, Hansen AG, Steffensen R, Jensenius JC. MAp19, the alternative splice product of the MASP2 gene. J Immunol Methods. 2011;373:89–101.
165. Møller-Kristensen M, Jensenius JC, Jensen L, et al. Levels of mannan-binding lectin-associated serine protease-2 in healthy individuals. J Immunol Methods. 2003;282:159–167.
166. Ammitzbøll CG, Steffensen R, Jørgen Nielsen H, et al. Polymorphisms in the MASP1 gene are associated with serum levels of MASP-1, MASP-3, and MAp44. PLoS ONE. 2013;8:e73317.
167. Seyfarth J, Garred P, Madsen HO. Extra-hepatic transcription of the human mannose-binding lectin gene (mbl2) and the MBL-associated serine protease 1-3 genes. Mol Immunol. 2006;43:962–971.
168. Skjoedt M-O, Palarasah Y, Munthe-Fog L, et al. MBL-associated serine protease-3 circulates in high serum concentrations predominantly in complex with Ficolin-3 and regulates Ficolin-3 mediated complement activation. Immunobiology. 2010;215:921–931.
169. Degn SE, Jensen L, Gál P, et al. Biological variations of MASP-3 and MAp44, two splice products of the MASP1 gene involved in regulation of the complement system. J Immunol Methods. 2010;361:37–50.
170. Skjoedt M-O, Hummelshoj T, Palarasah Y, et al. Serum concentration and interaction properties of MBL/ficolin associated protein-1. Immunobiology. 2011;216:625–632.
171. Kocsis A, Kékesi KA, Szász R, et al. Selective inhibition of the lectin pathway of complement with phage display selected peptides against mannose-binding lectin-associated serine protease (MASP)-1 and -2: significant contribution of MASP-1 to lectin pathway activation. J Immunol. 2010;185:4169–4178.
172. Héja D, Kocsis A, Dobó J, et al. Revised mechanism of complement lectin-pathway activation revealing the role of serine protease MASP-1 as the exclusive activator of MASP-2. Proc Natl Acad Sci USA. 2012;109:10498–10503.
173. Héja D, Harmat V, Fodor K, et al. Monospecific inhibitors show that both mannan-binding lectin-associated serine protease-1 (MASP-1) and -2 are essential for lectin pathway activation and reveal structural plasticity of MASP-2. J Biol Chem. 2012;287:20290–20300.
174. Degn SE, Jensen L, Hansen AG, et al. Mannan-binding lectin-associated serine protease (MASP)-1 is crucial for lectin pathway activation in human serum, whereas neither MASP-1 nor MASP-3 is required for alternative pathway function. J Immunol. 2012;189:3957–3969.
175. Kerr FK, Thomas AR, Wijeyewickrema LC, et al. Elucidation of the substrate specificity of the MASP-2 protease of the lectin complement pathway and identification of the enzyme as a major physiological target of the serpin, C1-inhibitor. Mol Immunol. 2008;45:670–677.
176. Takahashi M, Ishida Y, Iwaki D, et al. Essential role of mannose-binding lectin-associated serine protease-1 in activation of the complement factor D. J Exp Med. 2010;207:29–37.
177. Iwaki D, Kanno K, Takahashi M, Endo Y, Matsushita M, Fujita T. The role of mannose-binding lectin-associated serine protease-3 in activation of the alternative complement pathway. J Immunol. 2011;187:3751–3758.
178. Iwaki D, Kanno K, Takahashi M, et al. Small mannose-binding lectin-associated protein plays a regulatory role in the lectin complement pathway. J Immunol. 2006;177:8626–8632.
179. Gál P, Dobó J, Závodszky P. Sim RBM. Early complement proteases: C1r, C1s and MASPs. A structural insight into activation and functions. Mol Immunol. 2009;46:2745–2752.
180. Pavlov VI, Skjoedt M-O, Siow Tan Y, et al. Endogenous and natural complement inhibitor attenuates myocardial injury and arterial thrombogenesis. Circulation. 2012;126:2227–2235.
181. Banda NK, Mehta G, Kjaer TR, et al. Essential role for the lectin pathway in collagen antibody-induced arthritis revealed through use of adenovirus programming complement inhibitor MAp44 expression. J Immunol. 2014;193:2455–2468.
182. Stengaard-Pedersen K, Thiel S, Gadjeva M, et al. Inherited deficiency of mannan-binding lectin-associated serine protease 2. N Engl J Med. 2003;349:554–560.
183. Sokolowska A, Szala A, St Swierzko A, et al. Mannan-binding lectin-associated serine protease-2 (MASP-2) deficiency in two patients with pulmonary tuberculosis and one healthy control. Cell Mol Immunol. 2015;12:119–121.
184. García-Laorden MI, García-Saavedra A, de Castro FR, et al. Low clinical penetrance of mannose-binding lectin-associated serine protease 2 deficiency. J Allergy Clin Immunol. 2006;118:1383–1386.
185. Sirmaci A, Walsh T, Akay H, et al. MASP1 mutations in patients with facial, umbilical, coccygeal, and auditory findings of Carnevale, Malpuech, OSA, and Michels syndromes. Am J Hum Genet. 2010;87:679–686.
186. Schwaeble WJ, Lynch NJ, Clark JE, et al. Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury. Proc Natl Acad Sci USA. 2011;108:7523–7528.
187. Asgari E, Farrar CA, Lynch N, et al. Mannan-binding lectin-associated serine protease 2 is critical for the development of renal ischemia reperfusion injury and mediates tissue injury in the absence of complement C4. FASEB J. 2014;28:3996–4003.
188. Zhang M, Hou YJ, Cavusoglu E, et al. MASP-2 activation is involved in ischemia-related necrotic myocardial injury in humans. Int J Cardiol. 2013;166:499–504.
189. Krem MM, Di Cera E. Evolution of enzyme cascades from embryonic development to blood coagulation. Trends Biochem Sci. 2002;27:67–74.
190. Ambrus G, Gál P, Kojima M, et al. Natural substrates and inhibitors of mannan-binding lectin-associated serine protease-1 and -2: a study on recombinant catalytic fragments. J Immunol. 2003;170:1374–1382.
191. Hajela K, Kojima M, Ambrus G, et al. The biological functions of MBL-associated serine proteases (MASPs). Immunobiology. 2002;205:467–475.
192. Krarup A, Gulla KC, Gál P, Hajela K, Sim RB. The action of MBL-associated serine protease 1 (MASP1) on factor XIII and fibrinogen. Biochim Biophys Acta. 2008;1784:1294–1300.
193. Presanis JS, Hajela K, Ambrus G, Gál P, Sim RB. Differential substrate and inhibitor profiles for human MASP-1 and MASP-2. Mol Immunol. 2004;40:921–929.
194. Krarup A, Wallis R, Presanis JS, Gál P, Sim RB. Simultaneous activation of complement and coagulation by MBL-associated serine protease 2. PLoS ONE. 2007;2:e623.
195. Hess K, Ajjan R, Phoenix F, Dobó J, Gál P, Schroeder V. Effects of MASP-1 of the complement system on activation of coagulation factors and plasma clot formation. PLoS ONE. 2012;7:e35690.
196. Jenny L, Dobó J, Gál P, Schroeder V. MASP-1 of the complement system promotes clotting via prothrombin activation. Mol Immunol. 2015;65:398–405.
197. Dobó J, Major B, Kékesi KA, et al. Cleavage of kininogen and subsequent bradykinin release by the complement component: mannose-binding lectin-associated serine protease (MASP)-1. PLoS ONE. 2011;6:e20036.
198. Hansen CB, Csuka D, Munthe-Fog L, et al. The levels of the lectin pathway serine protease MASP-1 and its complex formation with C1 inhibitor are linked to the severity of hereditary angioedema. J Immunol. 2015;195:3596–3604.
199. Gulla KC, Gupta K, Krarup A, et al. Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot. Immunology. 2010;129:482–495.
200. Megyeri M, Makó V, Beinrohr L, et al. Complement protease MASP-1 activates human endothelial cells: PAR4 activation is a link between complement and endothelial function. J Immunol. 2009;183:3409–3416.
201. Kozarcanin H, Lood C, Munthe-Fog L, et al. The lectin complement pathway serine proteases (MASPs) represent a possible crossroad between the coagulation and complement systems in thromboinflammation. J Thromb Haemost. 2015;14:531–545.
202. Paréj K, Dobó J, Závodszky P, Gál P. The control of the complement lectin pathway activation revisited: both C1-inhibitor and antithrombin are likely physiological inhibitors, while α2-macroglobulin is not. Mol Immunol. 2013;54:415–422.
203. Takahashi K, Chang W-C, Takahashi M, et al. Mannose-binding lectin and its associated proteases (MASPs) mediate coagulation and its deficiency is a risk factor in developing complications from infection, including disseminated intravascular coagulation. Immunobiology. 2011;216:96–102.
204. La Bonte LR, Pavlov VI, Tan YS, et al. Mannose-binding lectin-associated serine protease-1 is a significant contributor to coagulation in a murine model of occlusive thrombosis. J Immunol. 2012;188:885–891.
205. Amara U, Flierl MA, Rittirsch D, et al. Molecular intercommunication between the complement and coagulation systems. J Immunol. 2010;185:5628–5636.